KDEV Oncology

KDEV Oncology is a preclinical-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting KDM5B (Lysine-specific demethylase 5B), an epigenetic regulator that plays a critical role in cancer cell survival, drug resistance, and immune evasion. By inhibiting KDM5B, KDEV Oncology aims to overcome resistance to existing therapies and enhance the efficacy of immunotherapy in various solid tumors, including breast and prostate cancer. The company's research is rooted in foundational discoveries from Yale University regarding the role of histone demethylases in oncology. KDEV Oncology is currently advancing its lead programs through lead optimization and early development stages.